Through our partners and recognized Centers of Excellence, we have access to best-in-class publications, continuing education, and online discussions. These tools support the HCMA's vision of providing support, advocacy, and education to patients, families, the medical community, and the public about hypertrophic cardiomyopathy, while supporting research and fostering the development of treatments.
This section of the website is dedicated to the medical community in support of those with HCM and associated spectrum disorders. Click on the logo of our partners to visit their educational outreach page.
The Hypertrophic Cardiomyopathy Association has partnered with PCM Scientific to present the HCM Education Academy, a ground-breaking medical education initiative designed to transform the identification, diagnosis, and management of patients with HCM by clinicians throughout the US. Education helps both the patient and provider make informed shared decisions in care. Our disease is manageable with the correct care and the HCM Academy will help increase the quality of care in your community, but only with your help!
HCM Academy will be OPEN November 2021
What You Will Learn
- How to distinguish HCM phenotypes
- Accurate cardiac imaging interpretation
- Monitor disease progression
- Treatment planning
- Shared decision-making techniques
- Considerations for sudden cardiac death
Hypertrophic cardiomyopathy or HCM is a primary myocardial disorder defined by left ventricular (LV) hypertrophy that cannot be explained by another cardiac or systemic disease. People with HCM face a risk of death more than 3 times greater than the average person of the same age without HCM.
Patients diagnosed with HCM are at increased risk for developing atrial fibrillation, suffering from stroke and even sudden cardiac arrest. It is estimated that 1 in every 500 people have HCM, but a large percentage of patients are undiagnosed. Learning more about HCM will ensure you are better able to discuss its impact with your patients.